Regeneron Pharmaceuticals
American pharmaceutical company
REGN Nasdaq
ISIN US75886F1075 SEC CIK 872589 LEI 549300RCBFWIRX3HYQ56
Follow Regeneron Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$5.1B
+36.3% vs same quarter last year
Net income
$1.9B
+33.5% vs same quarter last year
EPS, diluted
$18.45
+35.5% vs same quarter last year
Operating cash flow
$1.8B
+10.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $14.3B | $4.5B |
| FY24 | $14.2B | $4.4B |
| FY23 | $13.1B | $4B |
| FY22 | $12.2B | $4.3B |
| FY21 | $16.1B | $8.1B |
| FY20 | $8.5B | $3.5B |
| FY19 | $6.6B | $2.1B |
| FY18 | $5.1B | $2.4B |
| FY17 | $5.9B | $1.2B |
| FY16 | $4.9B | $895.5M |
| FY15 | $4.1B | $636.1M |
| FY14 | $2.8B | $338.1M |
| FY13 | $2.1B | $413.7M |
| FY12 | $1.4B | $750.3M |
| FY11 | $445.8M | −$221.8M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | - | 24.9% | 31.4% |
| FY24 | - | 28.1% | 31.1% |
| FY23 | - | 30.9% | 30.1% |
| FY22 | - | 38.9% | 35.6% |
| FY21 | - | 55.7% | 50.2% |
| FY20 | - | 42.1% | 41.3% |
| FY19 | 93.9% | 33.7% | 32.3% |
| FY18 | 95.4% | 49.3% | 47.5% |
| FY17 | 96.6% | 35.4% | 20.4% |
| FY16 | 96% | 27.4% | 18.4% |
| FY15 | 94.1% | 30.5% | 15.5% |
| FY14 | 95.4% | 29.2% | 12% |
| FY13 | 94.4% | 35.3% | 19.7% |
| FY12 | 93.9% | 33.2% | 54.4% |
| FY11 | 99.1% | −46% | −49.7% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $4.1B |
| FY24 | $3.7B |
| FY23 | $3.9B |
| FY22 | $4.4B |
| FY21 | $6.5B |
| FY20 | $2B |
| FY19 | $2B |
| FY18 | $1.8B |
| FY17 | $1B |
| FY16 | $974M |
| FY15 | $652.8M |
| FY14 | $419.4M |
| FY13 | $432.3M |
| FY12 | −$124M |
| FY11 | −$198.9M |
- Dividends
- Buybacks
Show the numbers
| Year | Dividends | Buybacks |
|---|---|---|
| FY25 | $370.3M | $3.4B |
| FY24 | $0 | $2.6B |
| FY23 | $0 | $2.2B |
| FY22 | - | $2.1B |
| FY21 | - | $1.6B |
| FY20 | - | $5.8B |
| FY19 | - | $275.9M |
| FY18 | - | $4.4M |
| FY17 | - | $0 |
| FY16 | - | $0 |
| FY15 | - | - |
| FY14 | - | - |
| FY13 | - | - |
| FY12 | - | - |
| FY11 | - | - |
- Regeneron Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Regeneron Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | 31.4% | −30.6% |
| FY24 | 31.1% | −47% |
| FY23 | 30.1% | −58% |
| FY22 | 35.6% | −80.4% |
| FY21 | 50.2% | −71.9% |
| FY20 | 41.3% | −62.2% |
| FY19 | 32.3% | −46.3% |
| FY18 | 47.5% | −49.6% |
| FY17 | 20.4% | −45.9% |
| FY16 | 18.4% | −36% |
| FY15 | 15.5% | −38.4% |
| FY14 | 12% | −35.5% |
| FY13 | 19.7% | −37.1% |
| FY12 | 54.4% | −29.1% |
| FY11 | −49.7% | −27.9% |